Loading patent…
AssigneeLcs Group, LLC
InventorLouis Sanfilippo
Estimating the term…
The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.
A method of treating binge eating disorder or obesity resulting from binge eating behavior, comprising diagnosing a patient as having a binge eating disorder or obesity resulting from binge eating behavior and providing an effective amount of amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog to the patient, wherein the amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is provided as the only active agent or is provided together with one or more additional active agents.
(canceled)
9-10. (canceled)
14-15. (canceled)
A method of using an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog comprising informing a user that the amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog may be used to treat binge eating disorder or obesity resulting from binge eating behavior.
(canceled)
21-23. (canceled)
A pharmaceutical composition comprising (i) lisdexamfetamine (L-lysine-D-amphetamine) dimesylate and (ii) one or more other active agent(s) combined in a single dosage form, wherein the other active agent is orlistat, topiramate, or zonisamide
A method of using an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog comprising (i) conducting a clinical trial of the efficacy of the amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog for treating the binge eating disorder or obesity resulting from binge eating behavior and (ii) informing a purchaser of the prodrug that the prodrug is efficacious for treating the binge eating disorder or obesity resulting from binge eating behavior.
(canceled)
Dependencies are inferred from the claim text.